University of Miami The Aging Brain: Navigating Cognition, Mental Health and Psychopharmacological Treatment 2025
- Differentiate between normal cognitive aging, mild cognitive impairment (MCI), and clinical dementia.
- Debate how to identify the underlying brain disorders causing clinical cognitive impairment in older adults.
- Identify the evidence-based, emerging brain biomarkers in cognitive disorders that help to diagnose at-risk older individuals for Alzheimer’s Disease and Related Dementias (ADRD).
- Identify the role of traditional and novel cognitive neuropsychological testing in early diagnosis of cognitive disorders in older individuals.
- Differentiate Alzheimer’s Disease from non- Alzheimer’s Disease pathology.
- Describe current pharmacological and nonpharmacological approaches to the treatment of Alzheimer’s Disease and Related Dementias (ADRD).
- Identify the emerging and promising agents in the treatment and management of early Alzheimer’s disease (AD).
- Recognize geriatric psychopharmacology and how to optimally treat the more challenging geriatric mental health conditions.
- Describe the promotion of brain health and longevity through evidence-based prevention.
- Differentiate between normal cognitive aging, mild cognitive impairment (MCI), and clinical dementia.
- Debate how to identify the underlying brain disorders causing clinical cognitive impairment in older adults.
- Identify the evidence-based, emerging brain biomarkers in cognitive disorders that help to diagnose at-risk older individuals for Alzheimer’s Disease and Related Dementias (ADRD).
- Identify the role of traditional and novel cognitive neuropsychological testing in early diagnosis of cognitive disorders in older individuals.
- Differentiate Alzheimer’s Disease from non- Alzheimer’s Disease pathology.
- Describe current pharmacological and nonpharmacological approaches to the treatment of Alzheimer’s Disease and Related Dementias (ADRD).
- Identify the emerging and promising agents in the treatment and management of early Alzheimer’s disease (AD).
- Recognize geriatric psychopharmacology and how to optimally treat the more challenging geriatric mental health conditions.
- Describe the promotion of brain health and longevity through evidence-based prevention.
| Sr No | Title | Time |
|---|---|---|
| 1 | Pharmacological Agents for Alzheimer’s Disease, Part 1: Symptomatic Management | 24:28 |
| 2 | Pharmacological Agents for Alzheimer’s Disease, Part 2: Disease Modification | 36:08 |
| 3 | Non-Pharmacological Management of Alzheimer’s and Related Dementias | 27:38 |
| 4 | Pharmacological Management of Agitation & Aggression in Alzheimer’s and Related Dementias | 32:26 |
| 5 | Overview of Common Neurodegenerative Disorders in Older Adults | 44:22 |
| 6 | Cognitive Changes That Occur in Normal Aging | 57:44 |
| 7 | Geriatric Pharmacology: Red Flag Drugs & Best Practices | 33:19 |
| 8 | Geriatric Pharmacology: Depression & Anxiety | 27:48 |
| 9 | Treating the Family Constellation in Geriatric Psychiatry and Dementia | 54:24 |
| 10 | New Breakthroughs in Cognitive Neuropsychological Assessment | 39:49 |
| 11 | Improving Cognition in Older People | 55:27 |
